Alkem Laboratories updates acquisition agreement for Occlutech Holding AG
Alkem Laboratories · Pharmaceuticals & Biotechnology
Key highlights
- Alkem Medtech Private Limited, Alkem's wholly owned subsidiary, plans to acquire 51%-55% stake in Occlutech Holding AG, Switzerland.
- Share Purchase Agreement initially dated 6th March 2026 with Occlutech's selling shareholders.
- First Supplementary Agreement to the Share Purchase Agreement executed on 26th June 2026.
Why it's rated notable: The filing states that a First Supplementary Agreement to the 6th March, 2026 Share Purchase Agreement was executed on 26th June, 2026, but gives no value and no description of the amended terms, so the level stays at the medium default.
Original filing
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Alkem Laboratories
- Acquisition / mergerNotableAlkem Laboratories completes acquisition of majority stake in Occlutech Holding AG
- Acquisition / mergerNotableAlkem Laboratories acquires 79,36,50,794 shares of Alkem Medtech via rights issue
- Fundraise / allotmentNotableAlkem Laboratories receives land allotment for new manufacturing facility in Ujjain
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.